FDA adds vision-loss warning to Ozempic, Wegovy and other GLP-1 drugs

The FDA is adding NAION vision-loss warnings to all marketed GLP-1 drugs, including Ozempic, Wegovy and Foundayo. Regulators describe the risk as very low, but causation remains unproven.